Assessment of Age-related Hearing Loss in HIV-1 Patients (HELO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02154971|
Recruitment Status : Recruiting
First Posted : June 4, 2014
Last Update Posted : February 14, 2017
The ageing process is known to be accelerated in HIV-infected patients, compared to the general population.
Normal age-related hearing loss (presbyacusia) is a frequent phenomenon, affecting more than 70% of people above 65 years. It is believed to be mostly the consequence of a mitochondrial damage caused by oxidative stress.
Risk factors for accelerated age-related hearing loss are present in many HIV-infected patients : chronic inflammation, smoking, diabetes, etc.
The global aim is to measure the prevalence of presbyacusia in a well controlled HIV positive population in France, and to compare it to HIV negative controls matched for age and sex.
90 HIV positive patients and 90 age- and sex- matched HIV negative controls will undergo a screening for presbyacusia (pure-tone, speech and evoked-response audiometry).
We expect to find an increased prevalence of presbyacusia in HIV-infected patients, as compared to controls matched for age and sex.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||180 participants|
|Official Title:||Assessment of Age-related Hearing Loss in HIV-1 Patients|
|Study Start Date :||November 2013|
|Estimated Primary Completion Date :||November 2017|
|Estimated Study Completion Date :||November 2017|
HIV infected for more than 10 years, aged over 40, treated with antiretroviral therapy
non-HIV (matched for age and gender)
- hearing loss at several frequencies [ Time Frame: Baseline ]Measurement by audiometry (pure tone and speech audiometry at 500Hz, 1000Hz, 2000Hz, 3000Hz and 8000 Hz), expressed in dB.
- threshold for speech intelligibility [ Time Frame: Baseline ]measured by speech audiometry
- Proportion of patients with neuropathic hearing loss [ Time Frame: Baseline ]
- Interval I-V on the evoked-response audiogram [ Time Frame: Baseline ]
- Maximum speech intelligibility [ Time Frame: Baseline ]Measured by speech audiometry
- Proportion of patients with age-related hearing loss [ Time Frame: Baseline ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02154971
|Contact: Antoine Moulignier, MD||+33 148 036 email@example.com|
|Fondation Ophtalmologique Adolphe de Rothschild||Recruiting|
|Paris, Ile de France, France, 75019|
|Principal Investigator:||Antoine Moulignier, MD||Fondation Ophtalmologique Antoine de Rothschild|